RVU — Ryvu Therapeutics SA Share News
0.000.00%
Last trade - 00:00- PLN319.98m
- PLN332.91m
- PLN62.25m
Brief: Ryvu Therapeutics Signs Cooperation, Licence And Investment Deal With BioNTech
Brief: Biontech And Ryvu Therapeutics To Develop And Commercialize Immuno-Modulatory Small Molecule Candidates
Brief: Ryvu Therapeutics Q3 Net Loss Narrows To 11.8 Mln Zlotys
Brief: Ryvu Therapeutics SA Says RVU120 Was Well Tolerated Across All Doses Evaluated
Brief: Ryvu Therapeutics To Issue Up To 4.8 Mln J Series Shares
Brief: Ryvu Therapeutics Q2 Net Loss Widens To 36.9 Mln Zlotys
Brief: Ryvu Therapeutics Presents Development Plans For 2022-2024
Brief: Ryvu Therapeutics Signs Financing Deal For Up To EUR 22 Mln With EIB
Brief: Ryvu Therapeutics Says Established Exclusive License Agreement With Exelixis To Develop Novel Sting Agonist-Based Targeted Cancer Therapies
Brief: Ryvu Therapeutics Presents Updated Data On RVU120 At 2022 EHA Congress
Brief: Ryvu Therapeutics Q1 Net Loss Widens To 26.5 Mln Zlotys
Brief: Ryvu Therapeutics FY Net Loss Widens To 77.5 Mln Zlotys
Brief: Selvita Unit Gets $4.7 Mln Order From US-Based Client
Brief: Ryvu Therapeutics Says Company To Receive Development Milestone Of EUR 1 Mln
Brief: Ryvu Therapeutics Gets Approval For Phase I/II Study Of RVU120 (SEL120) In Spain
Brief: Ryvu Therapeutics Signs Annex To Framework Deal With Icon Clinical Research Which Ups Total Deal Value To EUR 5.6 Mln
Brief: Ryvu Therapeutics Says Galapagos Exercises Option To License Inflammatory Disease Drug Program
Brief: Ryvu Therapeutics Partner Menarini Group Receives FDA Orphan Drug Designation
Brief: Ryvu Therapeutics Clinical and Translational Data Is Accepted For Presentation in US